Syncona Ltd. announced that Gian Piero Reverberi has been appointed as Non-Executive Director of the company, with effect from 1 April 2018. Mr. Reverberi brings over 20 years’ experience in the commercialisation of novel therapies through various roles at Vanda Pharmaceuticals, Shire, and Eli Lilly. Mr. Reverberi joined Vanda Pharmaceuticals in 2015 as SVP and Head of Europe before being appointed to SVP and Chief Commercial Officer. In this current role, he specialises in commercial strategy and new product planning, launching specialty and orphan drugs across a range of new markets internationally. Prior to Vanda Pharmaceuticals, he spent 10 years at Shire, seven of which as SVP, Head of International Specialty Pharma. Mr. Reverberi will continue to serve in his current role as SVP and Chief Commercial Officer at Vanda Pharmaceuticals. Syncona Ltd. also announces that Nick Moss has been appointed Senior Independent Director, with effect from 1 April 2018; and Robert Hutchinson has been appointed as the Chair of the Audit Committee with effect from 1 April 2018, succeeding Nick Moss.